Amneal Pharmaceuticals Inc (NASDAQ:AMRX) does about 1.47M shares in volume on a normal day but saw 1774313 shares change hands in the recent trading day. The company now has a market cap of 2.49B USD. Its current market price is $8.04, marking an increase of 1.64% compared to the previous close of $7.91. The 52 week high reached by this stock is $8.15 whilst the lowest price level in 52 weeks is $3.36. The script in recent trading has seen the stock touch a high of $9 and a low of $4.
Amneal Pharmaceuticals Inc (AMRX) has a 20-day trading average at $7.41 and the current price is -1.35% off the 52-week high compared with 139.29% distance from its 52-week low. The 50-day simple moving average of the closing price is $7.08 and its 200-day simple moving average is $5.95. If we look at the stock’s price movements over the week, volatility stands at 4.76%, which decreases to 4.42% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 65.46 to suggest the stock is neutral.
The consensus objective for the share price is $9.67, suggesting that the stock has a potential upside of 16.86% over the period. The median price target is -0.5% away from the current levels at $8.
1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 07, 2021 when RBC Capital Mkts resumed the stock to “Sector Perform” and issued a price target of $5. Goldman upgraded the stock to “Buy” from Sell on March 08, 2021 at a price target of $4-$6.50. Guggenheim upgraded its price target at $5.50.
Amneal Pharmaceuticals Inc (AMRX) stock is up 5.10% over the week and 9.84% over the past month. Its price is 32.45% year-to-date and 119.67% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0.13 and 0.6 for whole year. Expected sales for next quarter are $699.63M, which analysts say will come at $2.75B for the current fiscal year and next year at $2.84B. In addition, estimates put the company’s current quarterly revenue at an average of $694.17M.
Its 12-month price target is $8. To reach the target analysts have set, the stock logically needs to grow 16.86 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $4, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $9.
Outstanding shares total 306.56M with insiders holding 54.52% of the shares and institutional holders owning 44.24% of the company’s common stock. The company has a return on investment of -7.88% and return on equity of -133.96%. The forward price to earnings ratio is 11.53. The beta has a value of 1.17. Price to sales ratio is 0.96.
